Monoclonal Antibody Infusion Therapy for COVID-19 at Pardee
Pardee UNC Health Care is now offering Monoclonal Antibody infusion therapy (also known as REGEN-COV or Regeneron) for COVID-19 here locally in Western North Carolina. If you have been diagnosed with COVID-19 and are at high risk for developing severe COVID-19, you may be eligible for monoclonal antibody treatment, which might prevent you from becoming sicker. The Regneron treatment is a 20-minute infusion of monoclonal antibodies with a 60-minute observation period after infusion.
What Are Monoclonal Antibodies?
Antibodies are part of our natural defense against viruses such as SARS-CoV-2, the virus that causes COVID-19. But they take time for the body to make. Antibodies designed to attack COVID-19 have been developed, and in several studies have been shown to reduce the risk of progressing to severe COVID-19 and hospitalization when given early to people who test positive for COVID-19. This therapy is given as an infusion through an IV at a dedicated location at the hospital.
Eligibility Criteria for COVID 19 Monoclonal Antibody Infusion Therapy
To receive a Regeneron infusion, you must be at high risk for Severe COVID-19 and have
- a positive COVID test AND
- a referral from a Pardee Urgent Care provider.
The eligibility criteria for the infusion are very specific and must be verified by a Pardee Urgent Care provider prior to the referral. If a patient has received a positive test from another testing site, a copy must be brought to the appointment.
Once the patient’s COVID test results have been verified and the patient has seen one of the approved referring providers from Pardee Urgent Care, the patient will be referred to the Regeneron outpatient clinic. A scheduler will call the patient within 24 – 48 hours to set up the appointment. Patients will receive specific instructions for arrival and testing.
Monoclonal antibody therapy needs to be given as soon as possible after symptoms start to work—ideally within 4 days and no longer than 7 days.
For questions about the Regeneron process or treatment, or to find out more about eligibility, the community can call 828-694-8222. Learn more about monoclonal antibodies with this fact sheet from the FDA.